Cheryl Barton, a contributing writer for PharmTech Europe, highlights how European biotechs are using AI-driven target discovery to push respiratory treatment beyond broad immunosuppression toward ...
Across development, manufacturing, quality, and outsourcing, the pharma industry is being asked to scale complexity without sacrificing control. Pharmaceutical manufacturing is entering a phase ...
Revised recommendations address manufacturing-source submissions, immunogenicity-related testing, impurity thresholds, higher-order structure analyses, and bioactivity assessment, tightening the ...
Leading manufacturers now deploy validated agentic AI that detects OOS events, retrieves batch records, correlates prior deviations, and drafts RCA packages, yielding ≥50% faster investigations.
Six months in, pharma manufacturing and development experts reassess their 2026 outlooks and predict what comes next. The "China+1" strategy has evolved into a more aggressive push for multi-region ...
Pharma manufacturing and development experts reassess their 2026 predictions for the industry and look ahead to the second half of the year. As the pharmaceutical industry crosses the midpoint of 2026 ...
A Cambridge hub leverages dense co-location with universities, hospitals, and ~470 life science companies to compress translational cycles and expand collaboration in data-driven discovery and ...
The Impact of the FDA’s Single-Registration Pathway on Personalized Therapies, Part 1 Jason Bock, founder and CEO of CTMC, provides his perspective on the FDA’s proposed rule to streamline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results